Treatment for Non-Germinal Center (ABC) Diffuse Large B-Cell Lymphoma
For newly diagnosed non-germinal center B-cell (ABC) DLBCL, treat with polatuzumab vedotin-R-CHP (Pola-R-CHP) as first-line therapy, stratified by age and International Prognostic Index (IPI) risk score. 1
First-Line Treatment Algorithm
For Fit Patients (Age <80 years)
Standard approach:
- Pola-R-CHP is now preferred over R-CHOP for non-GCB DLBCL based on recent evidence showing improved outcomes 1
- Administer 6-8 cycles every 21 days 2
- Include 8 doses of rituximab total 2
Risk-stratified modifications:
- Low-risk (aa-IPI = 0, no bulky disease): 6 cycles of Pola-R-CHP or R-CHOP21 2
- Low-intermediate risk (aa-IPI = 1) or bulky disease: Either Pola-R-CHP/R-CHOP21 × 6 with radiotherapy to bulky sites, or intensified R-ACVBP 2
- High/high-intermediate risk (aa-IPI ≥ 2): 6-8 cycles Pola-R-CHP or R-CHOP21; consider clinical trial enrollment as priority 2
For Elderly Patients (Age 60-80 years)
- Perform comprehensive geriatric assessment first to determine fitness 2
- Fit patients: 6-8 cycles Pola-R-CHP or R-CHOP21 with 8 doses rituximab 2
- If using R-CHOP14: 6 cycles CHOP with 8 cycles rituximab suffice 2
For Very Elderly/Frail Patients (Age >80 years or unfit)
- R-miniCHOP is the standard attenuated regimen 2, 1
- Consider substituting or omitting doxorubicin (use gemcitabine, etoposide, or liposomal doxorubicin) for cardiac dysfunction or frailty 2
- Non-anthracycline regimens appropriate for very frail patients 1
Critical Management Principles
Avoid these common pitfalls:
- Never reduce doses for hematological toxicity when treating with curative intent 2
- Always use G-CSF prophylaxis in patients >60 years and those treated with curative intent to prevent febrile neutropenia 2
- Implement tumor lysis syndrome prophylaxis in high tumor burden cases 2
ABC-Specific Considerations
For non-GCB/ABC subtype specifically:
- Lenalidomide with rituximab and ibrutinib are particularly appropriate options at relapse for non-GCB DLBCL 3
- These agents target the activated B-cell pathway more effectively than in GCB subtypes
- Consider clinical trials combining R-CHOP with acalabrutinib for ABC-type DLBCL 4
CNS Prophylaxis
Administer CNS prophylaxis for:
- High-intermediate or high-risk IPI patients 2
- More than one extranodal site 2
- Elevated LDH 2
- Testicular, renal, or adrenal involvement 2
Method: Intravenous high-dose methotrexate (though evidence level is modest) 2
Response Assessment
- Use FDG-PET/CT as standard for post-treatment assessment 2
- Interim PET after 3-4 cycles may guide therapy escalation/de-escalation, though this remains under investigation 2, 1
- Biopsy residual metabolically active tissue before salvage treatment 2
Relapsed/Refractory Disease
For relapse <1 year or refractory disease:
- CAR T-cell therapy (axicabtagene ciloleucel or tisagenlecleucel) is the gold standard in second-line 3, 1
- This represents a paradigm shift from traditional salvage chemotherapy followed by autologous stem cell transplant
For relapse ≥1 year:
- Salvage chemotherapy followed by autologous stem cell transplant remains appropriate 1
- Second-line regimens should include rituximab if relapse occurs >6 months post-treatment and CD20 remains expressed 3
For transplant-ineligible or post-CAR-T progression:
- Bispecific antibodies (epcoritamab, mosunetuzumab, glofitamab) 4, 1
- Polatuzumab vedotin combinations 4
- Lenalidomide + rituximab (particularly effective in non-GCB) 3, 5
- Brentuximab vedotin + lenalidomide + rituximab 6
The evidence strongly supports Pola-R-CHP as the emerging standard for ABC/non-GCB DLBCL in first-line treatment, with the most recent guidelines 1 and reviews 7, 6 highlighting this shift. The traditional R-CHOP remains acceptable but appears inferior for this molecular subtype. Early integration of CAR-T therapy in second-line for aggressive relapses represents the most significant recent advancement in management strategy.